Management of hormonal therapy for the treatment of advanced hormone-dependent prostate cancer: A pharmacoeconomics assessment of the use of Degarelix – Firmagon® compared to generic triptorelin. Acta Med Peru [Internet]. 2024 May 20 [cited 2024 Dec. 25];28(4):188-93. Available from: https://amp.cmp.org.pe/index.php/AMP/article/view/1118